European Union funds SpheroTec

After having documented scientifically the high power of predictivity of SpheroTest in selecting the most suitable oncological drug for the individual cancer patient, Spherotec recieves a grant from the European Union’s Horizon 2020 research and innovation programme

Meet us at the San Antonio Breast Cancer Symposium

December 2014, San Antonio. This convention is the meeting point for the leading international breast cancer researchers to exchange the lates results and findingsAlso Spherotec will be there to present the exiting results achieved with SpheroTest for breast cancer patients.


One of our presentations will be: P3-06-13 Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – The SpheroNEO study
Halfter KML, Ditsch N, Kolberg H-C, Fischer H, Hauzenberger T, Edler von Koch F, Bauerfeind I, von Minckwitz G, Funke I, Crispin A, Mayer B. Department of Surgery, University Hospital of the LMU Munich, Munich, Germany; Department of Gynecology, University Hospital of the LMU Munich, Munich, Germany; Marienhospital Bottrop, Bottrop, Germany; Klinikum St. Marien Amberg, Amberg, Germany; Klinikum Dritter Orden, Department of Obstetrics and Gynecology, Munich, Germany; Klinikum Landshut, Landshut, Germany; GBG Forschungs GmbH, Neu-Isenburg and University Women's Hospital Frankfurt, Frankfurt, Germany; SpheroTec GmbH, Martinsried, Germany; Institute for Medical Informatics, Biometry and Epidemiology LMU, Munich, Germany

to the SABCS congress program


Contact

Call our experts for a free consultation: +49 89 540 41 34-0
spheromed@spherotec.com

Our lab and company
Our research services

Spheroselect - spheroids for anti-cancer drug selection